Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006

Published: 2009-06-10

Articles

State of Art on T-cell Lymphomas: The Epidemiology

R Liang

https://doi.org/10.4081/hmr.v2i13.474

150

PDF: 1167
- PDF
State of the Art on T-cell lymphomas: the Pathogenesis

ES Jaffe

https://doi.org/10.4081/hmr.v2i13.475

190

PDF: 571
- PDF
Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective

G Gisselbrecht

https://doi.org/10.4081/hmr.v2i13.476

139

PDF: 211
- PDF
Management of patients with peripheral T-cell lymphoma

JO Armitage

https://doi.org/10.4081/hmr.v2i13.477

165

PDF: 241
- PDF
Conventional treatment of peripheral T-cell lymphoma: the Asian perspective

K Tobinai

https://doi.org/10.4081/hmr.v2i13.478

151

PDF: 378
- PDF
T-cell lymphoma - standard treatment: The Mexican experience

A Avilès

https://doi.org/10.4081/hmr.v2i13.479

153

PDF: 284
- PDF
Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations

T Rüdiger

https://doi.org/10.4081/hmr.v2i13.480

176

PDF: 183
- PDF
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfrα deregulation

SA Pileri, PP Piccaluga, C Agostinelli, S Zupo, A Carbone, F Facchetti, B Falini, M Ferrarini

https://doi.org/10.4081/hmr.v2i13.481

168

PDF: 196
- PDF
Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

RL Piekarz, R Frye, M Turner, J Turner, S Allen, MH Kirschbaum, J Zain, M Prince

https://doi.org/10.4081/hmr.v2i13.482

191

PDF: 281
- PDF
Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

SJ Proctor, J Wilkinson

https://doi.org/10.4081/hmr.v2i13.483

203

PDF: 1172
- PDF
Forodesine – Preclinical Studies

V Gandhi

https://doi.org/10.4081/hmr.v2i13.484

132

PDF: 534
- PDF
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.485

232

PDF: 219
- PDF
Nelarabine – A New Age in the Management of Lymphoid Malignancies

MJ Keating

https://doi.org/10.4081/hmr.v2i13.486

194

PDF: 211
- PDF
New drugs for peripheral T-cell lymphomas

BD Cheson

https://doi.org/10.4081/hmr.v2i13.487

175

PDF: 275
- PDF
Cutaneous T-cell lymphomas: histology

M Santucci

https://doi.org/10.4081/hmr.v2i13.488

138

PDF: 135
- PDF
Molecular biology of cutaneous T-cell lymphomas

E Berti, S Gimelli, L Venegoni, V Merlo, R Riboni, O Zuffardi, M Paulli

https://doi.org/10.4081/hmr.v2i13.489

156

PDF: 192
- PDF
Alemtuzumab (Campath-1H)

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.490

136

PDF: 218
- PDF
Optimizing denileukin diftitox (Ontak®) therapy

M Duvic

https://doi.org/10.4081/hmr.v2i13.491

153

PDF: 703
- PDF
Gemcitabine

M Tani, E Marchi, M Fina

https://doi.org/10.4081/hmr.v2i13.492

154

PDF: 152
- PDF
Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects

U Wollina

https://doi.org/10.4081/hmr.v2i13.493

130

PDF: 371
- PDF
Interferons in cutaneous T-cell lymphomas

R Dummer, A Cozzio, M Urosevic

https://doi.org/10.4081/hmr.v2i13.494

146

PDF: 813
- PDF
Optimizing bexarotene therapy for cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i13.495

209

PDF: 689
- PDF
Bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v2i13.496

132

PDF: 172
- PDF
Animal models of T-cell lymphomas

Y-W Lin, PD Aplan

https://doi.org/10.4081/hmr.v2i13.497

165

PDF: 1181
- PDF
Rationale for the design of combination therapies that are active in T-cell lymphomas?

W Plunkett

https://doi.org/10.4081/hmr.v2i13.498

129

PDF: 134
- PDF
Peripheral T-cell lymphoma: prognostic factors

DD Weisenburger

https://doi.org/10.4081/hmr.v2i13.499

139

PDF: 362
- PDF
Prognostic factors in cutaneous T-cell lymphoma

R Willemze

https://doi.org/10.4081/hmr.v2i13.500

128

PDF: 827
- PDF
Chemotherapy for peripheral T-cell lymphoma

JM Vose

https://doi.org/10.4081/hmr.v2i13.501

130

PDF: 121
- PDF
Chemotherapy in cutaneous T-cell lymphoma

S Rupoli, MG Bernengo, R Alterini, M Cantonetti, PL Zinzani, N Pimpinelli

https://doi.org/10.4081/hmr.v2i13.502

165

PDF: 367
- PDF
Autotransplant in peripheral T-cell lymphomas

P Reimer

https://doi.org/10.4081/hmr.v2i13.503

128

PDF: 218
- PDF
Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome following reduced-intensity conditioning allogeneic stem cell transplantation

P Corradin, A Dodero, L Farina, M Casini, F Narni, F Patriarca, F Benedetti

https://doi.org/10.4081/hmr.v2i13.504

175

PDF: 186
- PDF
Auto and allotransplant in cutaneous T-cell lymphomas

F Onida

https://doi.org/10.4081/hmr.v2i13.505

147

PDF: 173
- PDF